HIV infection drives interferon signaling within intestinal SARS-CoV-2 target cells

Genomics Genomics
Immunology Immunology
Infectious Disease Infectious Disease
Alex K. Shalek Alex K. Shalek
Sarah Nyquist Sarah Nyquist

Fardoos et al.▾ Fardoos, R.*, Asowata, O.E.*, Herbert, N., Nyquist, S.K., Zungu, Y., Singh, A., Ngoepe, A., Mbano, I.M., Mthabela, N., Ramjit, D., Karim, F., Kuhn, W., Madela, F.G., Manzini, V.T., Anderson, F., Berger, B., Pers, T.H., Shalek, A.K., Leslie, A., Kløverpris, H.N.

JCI Insight , Volume 6

August, 2021

Abstract

SARS-CoV-2 infects epithelial cells of the human gastrointestinal (GI) tract and causes related symptoms. HIV infection impairs gut homeostasis and is associated with an increased risk of COVID-19 fatality. To investigate the potential link between these observations, we analyzed single-cell transcriptional profiles and SARS-CoV-2 entry receptor expression across lymphoid and mucosal human tissue from chronically HIV-infected individuals and uninfected controls. Absorptive gut enterocytes displayed the highest coexpression of SARS-CoV-2 receptors ACE2, TMPRSS2, and TMPRSS4, of which ACE2 expression was associated with canonical interferon response and antiviral genes. Chronic treated HIV infection was associated with a clear antiviral response in gut enterocytes and, unexpectedly, with a substantial reduction of ACE2 and TMPRSS2 target cells. Gut tissue from SARS-CoV-2–infected individuals, however, showed abundant SARS-CoV-2 nucleocapsid protein in both the large and small intestine, including an HIV-coinfected individual. Thus, upregulation of antiviral response genes and downregulation of ACE2 and TMPRSS2 in the GI tract of HIV-infected individuals does not prevent SARS-CoV-2 infection in this compartment. The impact of these HIV-associated intestinal mucosal changes on SARS-CoV-2 infection dynamics, disease severity, and vaccine responses remains unclear and requires further investigation.